A new, sound approach to tinnitus treatment

Tinnitus Care treats tinnitus with an innovative, FDA-cleared, non-invasive technique called Tinnitus Phase-Out™ treatment.

Treatment is available at The Hospital of St. John and St. Elizabeth (London, NW8) and other locations in the UK and internationally.

This unique therapy works through the identification of the patient's individual tinnitus soundwave and volume and the subsequent phase-shifting of these sound waves.

• Phase-Out™ treatment has undergone rigorous clinical testing.
• In October 2007, a peer-reviewed study at the University Hospital of Antwerp (UZA) in Belgium was published in B-ENT.
  This study, under the direction of Dr. Paul Van de Heyden, confirmed the findings of the earlier study (described below) that was published in Otolaryngology-Head and Neck Surgery in May 2007. Read the complete paper.
  
• A May 2007 peer-reviewed U.S. study in the medical journal Otolaryngology-Head and Neck Surgery stated,
  
  "RESULTS: Initial volume comparisons show a strong relationship
  between treatment and decrease in tinnitus intensity, with
  57% of patients achieving successful treatment. Thirty-seven percent decreased by one THI grade, 5% by two. Utilizing patient diaries, 42% of patients reported periods of complete residual inhibition (CRI) ranging from 1 hour to 7 days (average 2 days). No periods of CRI were reported in control weeks."
  
  "CONCLUSION: Phase-shift treatment significantly benefited
  the majority of our patients. These outcomes suggest that this device may be a valuable tool. Further long-term studies with home therapy are warranted." Read the complete paper.
  
  
• 83% of participants showed a positive response to Phase-Out™ treatment in an earlier U.S. study conducted in 2004/05.
• An equivalent U.K. Study showed another 70% positive response to Phase-Out™ treatment.
• There are no known complications resulting from Phase-Out™ treatment.
• Portable Home Treatment Device (Only 30 minutes needed per session).

The residual effect of the treatment has been shown to last, on average, about one week. Some patients have reported residual inhibition of symptoms for several weeks.